Cypex’s recombinant xenobiotic metabolizing enzymes complement BioIVT’s extensive portfolio of hepatocytes and related hepatic products for drug research and development
BioIVT, a leading provider of biospecimens, research models and services for drug and diagnostic development, today announced that it has acquired Cypex, a renowned manufacturer of recombinant xenobiotic metabolizing enzymes, based in Dundee, Scotland. Cypex’s extensive enzyme portfolio covers a wide range of proteins involved in drug metabolism.
“We are delighted that the Cypex team is joining BioIVT, bringing with them not…
Intellectual property offices worldwide are now enforcing the World Intellectual Property Organization (WIPO) Standard ST.26, which prescribes requirements for the presentation of nucleotide and amino acid sequence listings in patent applications. The new standard applies to patent applications filed on or after 1 July 2022 (the “big bang” date).
Standard ST.26 (hereinafter, “ST.26”) is intended to establish a single format for sequence listings that is acceptable worldwide and is compatible with international databases, such as those maintained by the International Nucleotide Sequence…
Leading global drug development consultancy Boyds has bolstered its US team with the appointment of experienced pharmaceutical product development professional Ami Patel PhD.
With more than 15 years’ experience in the pharmaceutical industry, Ami joins Boyds as Senior Director of Product Development based at the company’s Philadelphia office.
Ami has a PhD in Pharmaceutics from Long Island University, Brooklyn. Her career experience spans formulation research and development, business development and project management and technical consulting, with specialist expertise in product…
An independent study on European/UK growth stage Biotech remuneration
PIR International’s 2022 EU/UK Biotech Board & Executive Remuneration Study is a data-driven resource that empowers executives, investors and the boardroom with the insights they need to improve board governance, top-level business decisions and truly excel. This strictly independent, anonymised and confidential remuneration study is designed to leverage participation from the entire European and UK biotech ecosystem that will give the very latest data to drive important insights for all decision-makers in the sector.…
BioIVT, LLC (“BioIVT”), a leading global provider of biospecimens, cell and gene therapy related products, and research models and services for drug development purposes, today announced the promotion of Richard Haigh, PhD, to Chief Executive Officer (CEO) effective August 1. Dr. Haigh joined BioIVT in May 2022 as Chief Operating Officer and brings over 27 years’ experience in the life science research and diagnostics space covering products, consumables, and services, including over 15 years with Thermo Fisher Scientific/Life Technologies.
“I am delighted and honored to be taking on the…
Cambridge UK: 27 July 2022
RSM UK has become the latest Partner to join forces with One Nucleus. The One Nucleus Partner Programme is tailor-made to meet the needs of the One Nucleus Members, the Partner and One Nucleus in delivering on its core remit of supporting innovation.
Laragh Jeanroy, Managing Partner RSM East Anglia and Co-Head of Life Sciences at RSM commented
‘As a respected industry body for the life sciences industry and a key driver of business in the Cambridge and wider region, we are really pleased to become a partner of One Nucleus and excited to explore opportunities for…
Author: Helen Baxter, Vice President, North Highland
I joined fellow Life Science enthusiasts at the OnHelix conference in Cambridge at the beginning of the month to listen and learn to some of the latest thinking in Innovation in the industry. A range of experts talked about BioInnovation in the pharma and biotech industry at the latest OnHelix conference in Cambridge July 2022. Here are some of the key themes that emerged from the conference.
1. The convergence of technology into Life Sciences companies has critical and long reaching symptoms which are creating new opportunities for…
Sian Steele appointed Chair of the Boards of Howard Investments and Howard Ventures
Andrew Hynard appointed Non-Executive Director
Cambridge, 28th July 2022: Cambridge-based property developer and investor Howard Group is pleased to announce Sian Steele as its new Board Chair.
Sian will take up the position from 1st August after serving for the past two years as a Non-Executive Director of the Group.
Sian is well known in the Cambridge business community having previously worked as a Senior Partner in the Cambridge office for PwC, and has more than 30…
Cpl Life Sciences UK is proud to have been part of the trailblazer groups for the first clinical research apprenticeships in industry – Clinical Trial Specialist degree apprenticeship (Level 6), and the Regulatory Affairs Specialist (Level 7) both launched in 2019. It is part of our ongoing work and commitment to ensure the worsening skills shortages in the UK life sciences sectors are addressed, through proactive initiatives and programmes to bring in new talent and upskill/reskill current workforces. We have always been passionate about ‘giving back’ and have dedicated a…